In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN alpha treatment.
Eighteen patients with myeloproliferative syndrome (14 with chronic myeloid leukemia, four with essential thrombocytosis) were investigated for modulation of HLA antigens on peripheral blood lymphocytes, monocytes, and hematopoietic precursors during IFN alpha therapy as a sign of potentially increased immune recognition of malignant cells. After 1 month of IFN alpha therapy, an increased number of monocytes and hematopoietic precursor cells, but not of lymphocytes, expressed HLA-DQ antigens. In addition, a strong induction of HLA class-I antigens was found on both hematopoietic progenitors and normal peripheral blood mononuclear cells. With daily injections of IFN in the first month of therapy stimulation continuously increased, suggested a major effect of IFN alpha on hematopoietic progenitors with sustained enhanced expression of HLA class-I antigens during differentiation of myelomonocytic cells. HLA class-I antigen expression was consistently augmented by IFN alpha in all patients, irrespective of their hematological response.
Müller
C A
CA
Medizinische Klinik und Poliklinik, Abteilung II, Tübingen, Federal Republic of Germany.
Walz
J
J
Zinser
R
R
Bühring
H J
HJ
Steinke
B
B
Schmidt
H
H
D001772:Blood Cell Count; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D016898:Interferon-alpha / Q000627:therapeutic use*; D016131:Lymphocyte Subsets; D008297:Male; D009196:Myeloproliferative Disorders / Q000276:immunology* / Q000628:therapy
D006680:HLA Antigens; D016898:Interferon-alpha